Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BGE-117

            Therapeutic Area: Musculoskeletal

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: BioAge Labs

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 29, 2020

            Details:

            BioAge gets an exclusive worldwide license to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase inhibitor, BGE-117, to treat multiple diseases of aging.